Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 1
Submit an article Journal homepage
136
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Impact of multi-agent systemic therapy on all-cause and disease-specific survival for people living with HIV who are diagnosed with non-Hodgkin lymphoma: population-based analyses from the state of Georgia

Joseph Lipscomba Department of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, GA, USA;b Winship Cancer Institute, Emory University, Atlanta, GA, USACorrespondence[email protected]
View further author information
,
Jeffrey M. Switchenkob Winship Cancer Institute, Emory University, Atlanta, GA, USA;c Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, USAView further author information
,
Christopher R. Flowersd Division of Cancer Medicine, Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Theresa W. Gillespieb Winship Cancer Institute, Emory University, Atlanta, GA, USA;e Department of Surgical Oncology, Emory University School of Medicine, Atlanta, GA, USA;f Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USAView further author information
,
Pascale M. Wortleyg Georgia Department of Public Health, Atlanta, GAView further author information
,
A. Rana Bayaklyg Georgia Department of Public Health, Atlanta, GAView further author information
,
Lyn Almonh Georgia Center for Cancer Statistics, Rollins School of Public Health, Emory University, Atlanta, GA, USAView further author information
&
Kevin C. Wardh Georgia Center for Cancer Statistics, Rollins School of Public Health, Emory University, Atlanta, GA, USA;i Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USAView further author information
 show all
Pages 151-160 | Received 29 Jun 2022, Accepted 26 Sep 2022, Published online: 28 Oct 2022

References

  • Coghill AE, Strickler HD. Survival deficit for HIV-infected lymphoma patients in the National Cancer Database (editorial). Cancer Epidemiol Biomarkers Prev. 2017;26(3):289–290.
  • Coghill AE, Engels EA. Are cancers outcomes worse in the presence of HIV infection? (hypothesis/commentary). Cancer Epidemiol Biomarkers Prev. 2015;24(8):1165–1166.
  • Gibson TM, Morton LM, Shiels MS, et al. Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study. AIDS. 2014;28(15):2313–2318.
  • Gopal S, Martin KE, Richards KL, et al. Clinical presentation, treatment, and outcomes among 65 patients with HIV-associated lymphoma treated at the University of North Carolina, 2000-2010. AIDS Res Hum Retroviruses. 2012;28(8):798–805.
  • Sparano JA, Hu X, Wiernik PH, et al. Opportunistic infection and immunologic function in patients with human immunodeficiency virus-associated non-Hodgkin’s lymphoma with chemotherapy. J Natl Cancer Inst. 1997;89(4):301–307.
  • Re A, Cattaneo C, Rossi G. HIV and lymphoma: from epidemiology to clinical management. Mediterr J Hematol Infect Dis. 2019;11(1):e2019004.
  • Lipscomb J, Switchenko JM, Flowers CR, et al. Biologic, clinical, and sociodemographic predictors of multi-agent systemic therapy for non-Hodgkin lymphoma in people living with HIV: a population-based investigation in the state of Georgia. Leuk Lymphoma. 2020;61(4):896–904.
  • Suneja G, Shiels MS, Melville SK, et al. Disparities in the treatment and outcomes of lung cancer among HIV-infected individuals. AIDS. 2013;27(3):459–468.
  • Han X, Jemal A, Hulland E, et al. HIV infection and survival of lymphoma patients in the era of highly active antiretroviral therapy. Cancer Epidemiol Biomarkers Prev. 2017;26(3):303–311.
  • Jayakrishnan TT, Bakalov V, Samhouri Y, et al. Outcomes of treatment for HIV-infected lymphoma patients: a national cancer database (NCDB) analysis. Clinical Lymphoma, Myeloma & Leukemia. 2020;20(11):e864–e870.
  • National Cancer Institute, Division of Epidemiology and Genetics. HIV/AIDS Cancer Match Study. [cited 2021 Jun 25]. Available from: https://hivmatch.cancer.gov/.
  • Fogarasi J (SAS Institute). Fuzzy matching with SAS: data analysts’ tool to cleaner data. [cited 2021 July 7]. Available from: https://www.sas.com/content/dam/SAS/en_ca/User%20Group%20Presentations/TASS/fogarasi_fuzzy_matching.pdf.
  • National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-Hodgkin’s Lymphomas. Version 2. 2015. [cited 2021 Jul 8]. Available from: https://www2.tri-kobe.org/nccn/guideline/hematologic/nhl/english/foll.pdf.
  • Centers for Disease Control and Prevention, National Center for Health Statistics. National Death Index. [cited 2021 Jul 9]. Available from: https://www.cdc.gov/nchs/ndi/index.htm.
  • World Health Organization. 2004. ICD-10: international statistical classification of diseases and related health problems: tenth revision. 2nd ed. Geneva: World Health Organization.
  • Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509.
  • Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation. 2016;133(6):601–609.
  • Dignam JJ, Zhang Q, Kocherginsky M. The use and interpretation of competing risks regression models. Clin Cancer Res. 2012;18(8):2301–2308.
  • Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol. 2009;170(2):244–256.
  • Dal Maso L, Serraino D. All-cause and cancer-specific mortality among HIV-infected and HIV-uninfected patients with cancer. J Clin Oncol. 2016;34(4):388–390.
  • Coghill AE, Shiels MS, Suneja G, et al. Reply to L. Dal Maso et al. J Clin Oncol. 2016;34(4):390–391.
  • Lash TL, Cole SR. Immortal person-time in studies of cancer outcomes. J Clin Oncol. 2009;27(23):e55–e56.
  • Park HS, Gross CP, Makarov DV, et al. Immortal time bias: a frequently unrecognized threat to validity in the evaluation of post-operative radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83(5):1365–1373.
  • Giobbie-Hurder A, Gelber RD, Regan MM. Challenges of guarantee-time bias. J Clin Oncol. 2013;31(23):2963–2969.
  • Dafni U. Landmark analysis at the 25-year landmark point. Circ Cardiovasc Qual Outcomes. 2011;4(3):363–371.
  • Cortese G, Gerds TA, Andersen PK. Comparing predictions among competing risks models with time-dependent covariates. Stat Med. 2013;32(18):3089–3101.
  • Harrell FE. Jr. Regression modeling strategies, with application to linear models, logistic regression, and survival analysis. New York: Springer Series in Statistics, Springer-Verlag; 2015. p. 61.
  • Taplin SH, Price RA, Edwards HM, et al. Introduction: understanding and influencing multilevel factors across the cancer continuum. J Natl Cancer Inst Monogr. 2012;2012(44):2–10.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.